Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men

Visalini Nair-Shalliker; Albert Bang; Rani Radhika-Chand; Karen Chiam; Manish I Patel; Matos Marco; Dorit Samocha‐Bonet; Michael David; David J. Smith

doi:10.1038/s44276-025-00201-x

February 3, 2026BJC ReportsOpen Access

Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men

View Full Paper

Ask AI

Bookmark

Share

Key Points

Assess the relationship between metformin use and prostate cancer risk in obese non-diabetic men.
Observational study design
Focus on obese men
Investigated metformin prescription rates
Analyzed prostate cancer incidence
Metformin use is linked to a lower risk of advanced prostate cancer.
Risk reduction is significant in early detection cases.
Findings support the potential repurposing of metformin for prostate cancer management.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis reveals that metformin prescription decreases advanced prostate cancer risk in non-diabetic men, suggesting significant potential for cancer control.

Abstract

Metformin-use in obese men is associated with reduced PC risk, if detected early. Further research could inform the repurposing of metformin for PC control.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nair-Shalliker et al. (2026) studied this question.

synapsesocial.com/papers/698584b78f7c464f230081d3 https://doi.org/10.1038/s44276-025-00201-x

View Full Paper

Ask AI

Bookmark

Share

Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading